Chris Del Mar

Chris Del Mar

Auto-generated profile, based on publicly available information

Chris Del Mar

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Queensland, Australia

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JCJustin Clark
Justin Clark
PGPaul Glasziou
Paul Glasziou
CMChris Del Mar
Chris Del Mar
ABAlexandra Bannach-Brown
Alexandra Bannach-Brown
PSPaulina Stehlik
Paulina Stehlik
ASAnna Mae Scott
Anna Mae Scott

18 October 2006 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
KSKelly A Shaw
Kelly A Shaw
HGHanni C Gennat
Hanni C Gennat
POPeter O'ROurke
Peter O'ROurke
CMChris Del Mar
Chris Del Mar

1 February 2015 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
THTammy C. Hoffmann
Tammy C. Hoffmann
CMChris Del Mar
Chris Del Mar
Review from JAMA Internal Medicine — Patients’ Expectations of the Benefits and Harms of Treatments, Screening, and Tests — A Systematic Review

1 October 2014 in JAMA
Verified
Journal Article
Closed access
PDF file
THTammy C. Hoffmann
Tammy C. Hoffmann
VMVictor M. Montori
Victor M. Montori
CMChris Del Mar
Chris Del Mar
Opinion from JAMA — The Connection Between Evidence-Based Medicine and Shared Decision Making

21 April 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
Katy BellKaty Bell
Katy Bell
CMChris Del Mar
Chris Del Mar
GWGordon Wright
Gordon Wright
JDJames Dickinson
James Dickinson
PGPaul Glasziou
Paul Glasziou
Prostate cancer screening may detect nonprogressive cancers, leading to overdiagnosis and overtreatment. The potential for overdiagnosis can be assessed from the reservoir of prostate cancer in autopsy studies that report incidental prostate cancer rates in men who died of other causes. We aimed to estimate the age‐specific incidental cancer prevalence from all published autopsy studies. We identified eligible studies by searches of Medline and Embase, forward and backward citation searches and contacting authors. We screened the titles and abstracts of all articles; checked the full‐text articles for eligibility and extracted clinical and pathology data using standardized forms. We extracted mean cancer prevalence, age‐specific cancer prevalence and validity measures and then pooled data from all studies using logistic regression models with random effects. The 29 studies included in the review dated from 1948 to 2013. Incidental cancer was detected in all populations, with no obvious time trends in prevalence. Prostate cancer prevalence increased with each decade of age, OR = 1.7 (1.6–1.8), and was higher in studies that used the Gleason score, OR = 2.0 (1.1–3.7). No other factors were significantly predictive. The estimated mean cancer prevalence increased in a nonlinear fashion from 5% (95% CI: 3–8%) at age 79 years. There was substantial variation between populations in estimated cancer prevalence. There is a substantial reservoir of incidental prostate cancer which increases with age. The high risk of overdiagnosis limits the usefulness of prostate cancer screening.

1 October 1999 in The Lancet
Verified
Journal Article
Closed access
CAChris Allen
Chris Allen
PGPaul Glasziou
Paul Glasziou
CMChris Del Mar
Chris Del Mar